In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type. Hwang JH, Hsu CY. Ann Intern Med 2024;177:JC40.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hwang JH, Hsu CY. In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type. Ann Intern Med 2024;177:JC40.
PMID: 38560913